Combination therapies of fasn inhibitors with thyroid hormone receptor agonists
AssigneeSagimet Biosciences Inc.
InventorsAnne-Marie O'Farrell, George Kemble, Wen-Wei Tsai
Life of this patent
Estimating the term…
Abstract
Therapeutic combinations of fatty acid synthesis modulators and thyroid hormone receptor agonists are provided. The combinations may be used to treat disorders including metabolic disorders and liver disorders, such as nonalcoholic steatohepatitis/metabolic dysfunction-associated steatohepatitis (NASH/MASH).
Claims62
A method of treating steatotic liver disease in a subject in need thereof, the method comprising administering to the subject a fatty acid synthase inhibitor and a thyroid hormone receptor-beta agonist.
A method of treating nonalcoholic steatohepatitis/metabolic dysfunction-associated steatohepatitis (NASH/MASH) in a subject in need thereof, the method comprising administering to the subject a fatty acid synthase inhibitor and a thyroid hormone receptor-beta agonist.
A method of treating nonalcoholic fatty liver disease/metabolic dysfunction-associated steatotic liver disease (NAFLD/MASLD) in a subject in need thereof, the method comprising administering to the subject a fatty acid synthase inhibitor and a thyroid hormone receptor-beta agonist.
A method of treating metabolic syndrome in a subject in need thereof, the method comprising administering to the subject a fatty acid synthase inhibitor and a thyroid hormone receptor-beta agonist.
A method of treating Type II diabetes in a subject in need thereof, the method comprising administering to the subject a fatty acid synthase inhibitor and a thyroid hormone receptor-beta agonist.
A method of treating atherosclerosis in a subject in need thereof, the method comprising administering to the subject a fatty acid synthase inhibitor and a thyroid hormone receptor-beta agonist.
A method of treating liver cirrhosis in a subject in need thereof, the method comprising administering to the subject a fatty acid synthase inhibitor and a thyroid hormone receptor-beta agonist.
A method of treating liver cancer in a subject in need thereof, the method comprising administering to the subject a fatty acid synthase inhibitor and a thyroid hormone receptor-beta agonist.
A method of treating a disease or condition in which interleukin 1 beta (IL 1B) levels are elevated in a subject in need thereof, the method comprising administering to the subject a fatty acid synthase inhibitor and a thyroid hormone receptor-beta agonist.
A method of treating a disease or condition in which regulatory t cells (Treg) are reduced or suppressed in a subject in need thereof, the method comprising administering to the subject a fatty acid synthase inhibitor and a thyroid hormone receptor-beta agonist.
A method of treating a disease or condition in which t-helper (Th) cell levels are elevated in a subject in need thereof, the method comprising administering to the subject a fatty acid synthase inhibitor and a thyroid hormone receptor-beta agonist.
A method of reversing established nonalcoholic steatohepatitis/metabolic dysfunction-associated steatohepatitis (NASH/MASH) in a subject in need thereof, the method comprising administering to the subject a fatty acid synthase inhibitor and a thyroid hormone receptor-beta agonist.
A method of treating liver fibrosis in a subject in need thereof, the method comprising administering to the subject a fatty acid synthase inhibitor and a thyroid hormone receptor-beta agonist.
A method of reducing fibrotic gene expression in a subject in need thereof, the method comprising administering to the subject a fatty acid synthase inhibitor and a thyroid hormone receptor-beta agonist.
A method of reducing triglycerides in a subject in need thereof, the method comprising administering to the subject a fatty acid synthase inhibitor and a thyroid hormone receptor-beta agonist.
A method of improving or restoring liver function in a subject in need thereof, the method comprising administering to the subject a fatty acid synthase inhibitor and a thyroid hormone receptor-beta agonist.
A method of treating NASH/MASH with moderate to severe fibrosis in a subject in need thereof, the method comprising administering to the subject fatty acid synthase inhibitor and a thyroid hormone receptor-beta agonist.
A pharmaceutical formulation comprising Compound 001-152 (denifanstat) or a pharmaceutically acceptable salt thereof and Compound A (resmetirom) or a pharmaceutically acceptable salt thereof.
A pharmaceutical formulation comprising Compound 001-152 (denifanstat) or a pharmaceutically acceptable salt thereof and a polymorph of Form A of the Compound A (resmetirom).
A pharmaceutical formulation comprising a FASN inhibitor or a pharmaceutically acceptable salt thereof and a thyroid hormone receptor agonist or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.